Physician profile
Luke Killpack
NPI 1679955041
$7,097.64
in general payments reported to CMS, 2019-2025
28 companies · $2,620 in 2025
The $2,620 reported for 2025 was more than what 82% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $426 · 2020: $57.85 · 2021: $280 · 2022: $811 · 2023: $1,352 · 2024: $1,550 · 2025: $2,620.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,195 · Education: $327.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,195.30 |
| Education | $326.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,090.80 | 2019-2025 | |
| Janssen Biotech, INC. | $1,033.69 | 2021-2025 | Tremfya, Stelara, Simponi Aria |
| Regeneron Healthcare Solutions, INC. | $991.96 | 2019-2025 | Dupixent, Libtayo |
| Lilly USA, LLC | $684.42 | 2021-2025 | Taltz, Ebglyss, Olumiant |
| Novartis Pharmaceuticals Corporation | $647.47 | 2019-2025 | |
| Amgen INC. | $414.66 | 2020-2025 | Otezla, Otezla |
| Pfizer INC. | $392.78 | 2021-2025 | |
| Genzyme Corporation | $217.98 | 2022-2025 | |
| Sun Pharmaceutical Industries INC. | $212.44 | 2023-2025 | Ilumya |
| Ucb, INC. | $200.12 | 2019-2025 | Bimzelx |
| Leo Pharma INC. | $190.83 | 2022-2025 | Adbry |
| Incyte Corporation | $185.39 | 2022-2025 | Opzelura |
| Galderma Laboratories, L.P. | $184.75 | 2024-2025 | Nemluvio |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $155.73 | 2019-2020 | |
| Dermavant Sciences, INC. | $146.16 | 2023-2024 | Vtama |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $63.86 | 2023-2024 | Sotyktu |
| Boehringer Ingelheim Pharmaceuticals, INC. | $46.92 | 2022 | |
| Arcutis Biotherapeutics, INC. | $45.94 | 2024 | Zoryve |
| Organon LLC | $29.32 | 2025 | |
| Biowound Solutions, INC. | $28.09 | 2025 | Bio-Connekt |
| Sanofi-Aventis U.S. LLC | $22.94 | 2019 | |
| Lnhc, INC | $22.03 | 2025 | Zelsuvmi |
| Genentech USA, INC. | $20.90 | 2024 | Xolair |
| Mayne Pharma Commercial LLC | $16.92 | 2023-2025 | |
| Almirall LLC | $15.70 | 2025 | Klisyri |
| Integra Lifesciences Corporation | $13.06 | 2019 | |
| Celgene Corporation | $12.40 | 2019 | |
| Prugen, INC. Pharmaceuticals | $10.38 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Luke Killpack listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.